Irinotecan Hydrochloride Accord-Uk

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Hydrochloride Accord-Uk, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is used in the management of metastatic colorectal cancer and a range of advanced solid tumours, typically in combination with other chemotherapeutic agents.

GNH USA supplies Irinotecan Hydrochloride Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality‑controlled distribution and regulatory compliance for clinical use through robust cold‑chain logistics where required.

Irinotecan Hydrochloride is a topoisomerase I inhibitor used in chemotherapy for gastrointestinal and other solid tumors.

Metastatic colorectal cancer: improves response rates and overall survival when combined with fluoropyrimidine‑based regimens. Advanced gastric cancer: used as part of combination therapy to achieve tumor shrinkage. Advanced pancreatic cancer: incorporated into multi‑drug protocols to enhance disease control.

Irinotecan Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: often delayed and may be severe. - Neutropenia: reduced white blood cell count. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Fatigue: generalized tiredness. - Alopecia: hair loss in some patients. - Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count. - Severe colitis or intestinal perforation. - Hepatotoxicity: elevated liver enzymes or bilirubin. - Allergic reactions: rash, urticaria, or anaphylaxis. - Severe electrolyte disturbances: especially hypokalemia. - Cardiac events: rare cases of arrhythmia or ischemia.

When using Irinotecan Hydrochloride, careful monitoring and supportive measures are essential.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: evaluate hepatic enzymes before and during therapy. Hydration: maintain adequate fluid intake to reduce risk of severe diarrhea. Avoid concurrent myelosuppressive agents unless clinically indicated. Pregnancy and lactation: use only if potential benefit justifies risk; consult specialist. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): increase toxicity risk. - Concurrent use of other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Fluoropyrimidines (5‑FU, capecitabine): increased myelosuppression. - CYP3A4‑inducing antiemetics (e.g., dexamethasone): may reduce efficacy. - Warfarin: monitor INR due to potential interaction.